On August 21, 2020 Genome & Company (CEO Bae Bae Soo, Park Han Soo) reported that a domestic patent application for its flagship pipeline’GEN-001′ has been patented (Press release, Genome & Company, AUG 21, 2020, View Source [SID1234563922]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this patent decision, Genome & Company has secured exclusive rights for GEN-001, the main pipeline, not only for the strain itself, but also for GEN-001 alone and in combination with chemo/immuno-cancer drugs.

GEN-001 is a candidate substance for oral microbiome treatment and has immune activity, and is being developed as an anticancer agent as a combination therapy with an immune checkpoint inhibitor. GEN-001 is a single strain of bacteria isolated from healthy volunteers and has been found to activate dendritic cell, macrophage, and T cell responses. In the preclinical stage, GEN-001 has secured optimal safety, and in particular, when administered in combination with an immune checkpoint inhibitor (ICI), it has a synergistic effect that significantly inhibits cancer growth in models that respond to existing immune checkpoint inhibitors and models that do not respond. Showed.

Genome & Company is the first in Korea to conduct a combined clinical trial for cancer patients with Merck/Pfizer’s immune anticancer drug (Abelumab) after approval of the US Food and Drug Administration (FDA) clinical trial plan (IND) as an anticancer microbiome in April 2020. Is in progress.

Park Han-soo, CEO of R&D, said, "It is of great significance not only for the anticancer microbiome itself, but also for obtaining a patent decision for single or combined administration regardless of carcinoma. Through development, we will become a company that can give hope to cancer patients."